1 report

  • 05/08/2018: Intellipharmaceutics Announces Start of Intranasal Human Abuse Liability Studies for Oxycodone ER
  • Jun 30, 2017: Intellipharmaceutics Announces FDA Advisory Committee Meeting for Rexista an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain

Each unit is comprised of one common share (or common share equivalent) and one warrant to purchase one common share.

  • Analgesic
  • Canada
  • United States
  • Corporate Finance
  • Intellipharmaceutics International Inc.